中枢神経系医薬品市場：薬剤クラス別、疾患別、薬剤タイプ別、流通チャネル別-2025-2030年世界予測

中枢神経系医薬品市場は、2023年に207億1,000万米ドルと評価され、2024年には224億4,000万米ドルに達すると予測され、2030年には399億9,000万米ドルにまでCAGR 9.85%で成長すると予測されています。

中枢神経系（CNS）医薬品は、脳と脊髄に影響を及ぼす疾患の治療を目的とする医薬品の中でも重要な領域を包含します。この分野は、神経変性疾患、精神疾患、疼痛管理などの治療を含む幅広い医薬品をカバーしています。中枢神経系治療薬の必要性は、神経疾患や精神疾患の有病率の増加、慢性疼痛の効果的な管理の必要性、神経技術の進歩によってもたらされています。用途はアルツハイマー病、パーキンソン病、うつ病、不安神経症、多発性硬化症、てんかんなど多岐にわたり、満たされていない医療ニーズに対応し、患者のQOLを向上させる。最終用途の範囲は病院、診療所、在宅介護まで及び、中枢神経系障害の影響を受けている老人、小児、成人の集団からの取り込みが顕著です。この市場に影響を与える主な成長要因としては、人口動態の高齢化、メンタルヘルスに対する意識の高まり、ヘルスケア支出の増加、精密医療やバイオマーカー同定などの技術革新などが挙げられます。最近の潜在的なビジネスチャンスは、生物製剤や遺伝子治療の開発、創薬や個別化医療のための人工知能の活用にあります。企業は戦略的パートナーシップや研究開発に投資することで、これらを活用することができます。しかし、研究開発コストの高さ、規制の枠組みの厳しさ、神経学的研究の複雑さなどが市場成長の課題となっています。神経保護療法、バイオシミラー、ドラッグデリバリーシステムの強化といった分野、特に神経腫瘍学や希少中枢神経系疾患の分野では、イノベーションと研究が盛んになる可能性があります。中枢神経系疾患治療薬市場は多様で急速に進化しており、企業は規制状況、競合情勢、デジタルヘルス技術の統合を先取りする必要があります。このような複雑な状況を乗り切り、成長を実現するためには、企業は患者中心のアプローチを優先し、最先端の研究に投資し、治療パイプラインと新興市場へのアクセスを強化する共同研究を模索する必要があります。

市場力学：急速に進化する中枢神経系医薬品市場の主要市場インサイトを公開

中枢神経系医薬品市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界中で増加する神経障害および認知障害の発生率
  • 神経学的危険因子や症状に関する知識を広めるための政府プログラムや啓発活動の増加
  • 神経学的合併症を持つ老年人口の増加
• 市場抑制要因
  • 創薬・開発には高額な設備投資と十分なインフラが必要
• 市場機会
  • 精神科・神経科領域特有の変化する需要に対応するための継続的な薬剤の進化
  • 中枢神経系の創薬における人工知能と機械学習の採用
• 市場の課題
  • 製品承認のための厳しい規制と製品回収に関する懸念
  • 有能な研究が行われているにもかかわらず、神経学分野の専門知識が乏しいこと

ポーターの5つの力：中枢神経系医薬品市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：中枢神経系医薬品市場における外部からの影響の把握

外部マクロ環境要因は、中枢神経系医薬品市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析中枢神経系医薬品市場における競合情勢の把握

中枢神経系医薬品市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス中枢神経系医薬品市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、中枢神経系医薬品市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨中枢神経系医薬品市場における成功への道筋を描く

中枢神経系医薬品市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で神経疾患や認知障害の発生率が増加
    • 神経学的危険因子と症状に関する知識を広めるための政府のプログラムと啓発活動の増加
    • 神経学的合併症を伴う高齢者人口の増加
  • 抑制要因
    • 医薬品の発見と開発には多額の資本投資と適切なインフラが必要
  • 機会
    • 精神医学と神経学の分野における独特で変化する要求を満たすための継続的な薬剤開発
    • CNS創薬における人工知能と機械学習の導入
  • 課題
    • 製品承認に関する厳格な規制と製品リコールに関する懸念
    • 有能な研究があるにもかかわらず、神経学の分野における主題の専門知識が不足している
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 中枢神経系医薬品市場薬物クラス別

• 鎮痛剤
• 麻酔薬
• 抗てんかん薬
• 抗パーキンソン病薬
• 抗うつ薬

第7章 中枢神経系医薬品市場病気別

• 中枢神経系外傷
• 感染症
• メンタルヘルス
• 神経変性疾患
• 神経血管疾患

第8章 中枢神経系医薬品市場薬の種類別

• 生物学的製剤
• 非生物製剤

第9章 中枢神経系医薬品市場：流通チャネル別

• 病院薬局
• オンライン
• 小売薬局

第10章 南北アメリカの中枢神経系医薬品市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の中枢神経系医薬品市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの中枢神経系医薬品市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • アステックスとカーディフ大学が新薬発見の協力を発表
  • ニューラックスファーム、サノフィからの既存製品の買収完了を発表
  • プレシジョンライフと小野薬品工業、中枢神経系疾患のマルチターゲットパートナーシップを締結
  • 協力は中枢神経系疾患の治療目標に焦点を当てる
  • イントリンシック・メディシンがフェニックス・バイオテックと合併契約を締結
  • ソリッドバイオサイエンス、AavantiBioの買収と同時7,500万米ドルの私募を発表
  • ジェンサイクが開発協力を開始
  • IAMA Therapeuticsはイタリア工科大学と提携し、神経科学の創薬に関する画期的な調査に着手します。
  • アッヴィとゲデオン・リヒターが神経精神疾患分野での提携を発表
  • アッヴィ、シンデシ・セラピューティクスを買収し、神経科学ポートフォリオを強化
• 戦略分析と提言

企業一覧

• A. N. Pharmacia Laboratories Pvt. Ltd.
• AbbVie Inc.
• Alkermes PLC
• Apotex Inc.
• Arvelle Therapeutics International GmbH by Angelini Pharma Inc.
• AstraZeneca PLC
• Aurobindo Pharma
• BIAL-PORTELA & CA, S.A.
• Biogen Inc.
• Catalent, Inc.
• CNS Pharmaceuticals, Inc.
• Daiichi Sankyo Company, Limited
• Divi's Laboratories Ltd.
• Dr. Reddy's Laboratories Ltd.
• East India Pharmaceutical Works Ltd.
• Eisai Co., Ltd.
• Eli Lilly and Company
• Endo International PLC by DuPont de Nemours, Inc.
• Eridanus Healthcare
• EVERSANA
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• H. Lundbeck A/S
• Intas Pharmaceuticals Ltd.
• Jabs Biotech Pvt. Ltd.
• Johnson & Johnson Services, Inc.
• La Renon Healthcare Pvt. Ltd.
• Lupin Ltd.
• Merck & Co.
• Micro Labs Ltd.
• Midas Pharma GmbH
• Neuracle Lifesciences Private Limited
• Neurocon Inc.
• Novartis Group
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Priavoid GmbH
• Reliance Formulations Pvt. Ltd.
• Sanofi S.A.
• Servier Laboratories（Aust）Pty Ltd
• Shine Pharmaceuticals Ltd.
• Somacare
• SteriMax Inc.
• Sun Pharmaceuticals Pvt Ltd.
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• UCB S.A.
• Wellona Pharma
• Zee Laboratories Limited

LIST OF FIGURES

• FIGURE 1. CENTRAL NERVOUS SYSTEM DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CENTRAL NERVOUS SYSTEM DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CENTRAL NERVOUS SYSTEM DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CENTRAL NERVOUS SYSTEM DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CENTRAL NERVOUS SYSTEM DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANESTHETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTI-PARKINSON DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS TRAUMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MENTAL HEALTH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NEUROVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 40. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 41. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 42. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 62. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 63. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 64. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 66. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 67. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 68. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 135. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 136. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 137. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 150. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 151. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 152. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 153. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 154. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 155. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 156. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 157. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 194. CENTRAL NERVOUS SYSTEM DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 195. CENTRAL NERVOUS SYSTEM DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Central Nervous System Drugs Market was valued at USD 20.71 billion in 2023, expected to reach USD 22.44 billion in 2024, and is projected to grow at a CAGR of 9.85%, to USD 39.99 billion by 2030.

Central Nervous System (CNS) Drugs encompass a critical domain within pharmaceuticals aimed at treating disorders affecting the brain and spinal cord. This segment covers a broad range of medications, including treatments for neurodegenerative diseases, mental health disorders, and pain management. The necessity for CNS drugs is driven by the growing prevalence of neurological and psychiatric conditions, the need for effective management of chronic pain, and advancements in neurotechnology. Applications range across Alzheimer's, Parkinson's, depression, anxiety, multiple sclerosis, and epilepsy, addressing unmet medical needs and enhancing patient quality of life. The end-use scope extends to hospitals, clinics, and home care settings, with significant uptake from geriatric, pediatric, and adult populations impacted by CNS disorders. Key growth factors influencing this market include an aging demographic, increased mental health awareness, rising healthcare expenditures, and technological innovations such as precision medicine and biomarker identification. Recent potential opportunities lie in developing biologics, gene therapies, and leveraging artificial intelligence for drug discovery and personalized medicine. Companies can capitalize on these by investing in strategic partnerships and R&D. However, market growth is challenged by high R&D costs, stringent regulatory frameworks, and the complexity of neurological research, which result in longer timelines and uncertain outcomes. Innovation and research can thrive in areas like neuroprotective therapies, biosimilars, and enhancing drug delivery systems, particularly within neuro-oncology and rare CNS disorders. The CNS drugs market is diverse and rapidly evolving, requiring businesses to stay ahead of regulatory landscapes, competitive dynamics, and the integration of digital health technologies. To navigate these complexities and capitalize on growth, firms must prioritize patient-centric approaches, invest in cutting-edge research, and explore collaborations that enhance therapeutic pipelines and access to emerging markets.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Central Nervous System Drugs Market

The Central Nervous System Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing incidence of neurological and cognitive disorders across the globe
  • Ascending government programs and awareness activities to spread the knowledge about neurological risk factors and symptoms
  • Rise in geriatric population with neurological complications
• Market Restraints
  • Requirement of high capital investment and adequate infrastructure for drug discovery and development
• Market Opportunities
  • Ongoing drug evolvement to meet the unique and changing demands of psychiatry and neurology field
  • Adoption of artificial intelligence and machine learning in CNS drug discovery
• Market Challenges
  • Stringent regulations for product approvals and concern regarding product recalls
  • Dearth of subject expertise in the neurological field amid the competent studies

Porter's Five Forces: A Strategic Tool for Navigating the Central Nervous System Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Central Nervous System Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Central Nervous System Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Central Nervous System Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Central Nervous System Drugs Market

A detailed market share analysis in the Central Nervous System Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Central Nervous System Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Central Nervous System Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Central Nervous System Drugs Market

A strategic analysis of the Central Nervous System Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Central Nervous System Drugs Market, highlighting leading vendors and their innovative profiles. These include A. N. Pharmacia Laboratories Pvt. Ltd., AbbVie Inc., Alkermes PLC, Apotex Inc., Arvelle Therapeutics International GmbH by Angelini Pharma Inc., AstraZeneca PLC, Aurobindo Pharma, BIAL - PORTELA & CA, S.A., Biogen Inc., Catalent, Inc., CNS Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Divi's Laboratories Ltd., Dr. Reddy's Laboratories Ltd., East India Pharmaceutical Works Ltd., Eisai Co., Ltd., Eli Lilly and Company, Endo International PLC by DuPont de Nemours, Inc., Eridanus Healthcare, EVERSANA, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, H. Lundbeck A/S, Intas Pharmaceuticals Ltd., Jabs Biotech Pvt. Ltd., Johnson & Johnson Services, Inc., La Renon Healthcare Pvt. Ltd., Lupin Ltd., Merck & Co., Micro Labs Ltd., Midas Pharma GmbH, Neuracle Lifesciences Private Limited, Neurocon Inc., Novartis Group, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Priavoid GmbH, Reliance Formulations Pvt. Ltd., Sanofi S.A., Servier Laboratories (Aust) Pty Ltd, Shine Pharmaceuticals Ltd., Somacare, SteriMax Inc., Sun Pharmaceuticals Pvt Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., UCB S.A., Wellona Pharma, and Zee Laboratories Limited.

Market Segmentation & Coverage

This research report categorizes the Central Nervous System Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Classes, market is studied across Analgesics, Anesthetics, Anti-Epileptics, Anti-Parkinson Drugs, and Antidepressant.
• Based on Diseases, market is studied across CNS Trauma, Infectious Diseases, Mental Health, Neurodegenerative Diseases, and Neurovascular Diseases.
• Based on Drug Type, market is studied across Biologics and Non-Biologics.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing incidence of neurological and cognitive disorders across the globe
    • 5.1.1.2. Ascending government programs and awareness activities to spread the knowledge about neurological risk factors and symptoms
    • 5.1.1.3. Rise in geriatric population with neurological complications
  • 5.1.2. Restraints
    • 5.1.2.1. Requirement of high capital investment and adequate infrastructure for drug discovery and development
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing drug evolvement to meet the unique and changing demands of psychiatry and neurology field
    • 5.1.3.2. Adoption of artificial intelligence and machine learning in CNS drug discovery
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations for product approvals and concern regarding product recalls
    • 5.1.4.2. Dearth of subject expertise in the neurological field amid the competent studies
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Central Nervous System Drugs Market, by Drug Classes

• 6.1. Introduction
• 6.2. Analgesics
• 6.3. Anesthetics
• 6.4. Anti-Epileptics
• 6.5. Anti-Parkinson Drugs
• 6.6. Antidepressant

7. Central Nervous System Drugs Market, by Diseases

• 7.1. Introduction
• 7.2. CNS Trauma
• 7.3. Infectious Diseases
• 7.4. Mental Health
• 7.5. Neurodegenerative Diseases
• 7.6. Neurovascular Diseases

8. Central Nervous System Drugs Market, by Drug Type

• 8.1. Introduction
• 8.2. Biologics
• 8.3. Non-Biologics

9. Central Nervous System Drugs Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacies
• 9.3. Online
• 9.4. Retail Pharmacies

10. Americas Central Nervous System Drugs Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Central Nervous System Drugs Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Central Nervous System Drugs Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Astex and Cardiff University announce drug discovery collaboration
  • 13.3.2. Neuraxpharm announces closing of acquisition of established products from Sanofi
  • 13.3.3. PrecisionLife and Ono sign multi-target partnership for CNS disorders
  • 13.3.4. Collaboration will focus on therapy targets for CNS disorders
  • 13.3.5. Intrinsic Medicine enters merger deal with Phoenix Biotech
  • 13.3.6. Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
  • 13.3.7. Gensaic enters into collaboration to develop
  • 13.3.8. IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery
  • 13.3.9. AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases
  • 13.3.10. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. A. N. Pharmacia Laboratories Pvt. Ltd.
• 2. AbbVie Inc.
• 3. Alkermes PLC
• 4. Apotex Inc.
• 5. Arvelle Therapeutics International GmbH by Angelini Pharma Inc.
• 6. AstraZeneca PLC
• 7. Aurobindo Pharma
• 8. BIAL - PORTELA & CA, S.A.
• 9. Biogen Inc.
• 10. Catalent, Inc.
• 11. CNS Pharmaceuticals, Inc.
• 12. Daiichi Sankyo Company, Limited
• 13. Divi's Laboratories Ltd.
• 14. Dr. Reddy's Laboratories Ltd.
• 15. East India Pharmaceutical Works Ltd.
• 16. Eisai Co., Ltd.
• 17. Eli Lilly and Company
• 18. Endo International PLC by DuPont de Nemours, Inc.
• 19. Eridanus Healthcare
• 20. EVERSANA
• 21. F. Hoffmann-La Roche AG
• 22. GlaxoSmithKline PLC
• 23. H. Lundbeck A/S
• 24. Intas Pharmaceuticals Ltd.
• 25. Jabs Biotech Pvt. Ltd.
• 26. Johnson & Johnson Services, Inc.
• 27. La Renon Healthcare Pvt. Ltd.
• 28. Lupin Ltd.
• 29. Merck & Co.
• 30. Micro Labs Ltd.
• 31. Midas Pharma GmbH
• 32. Neuracle Lifesciences Private Limited
• 33. Neurocon Inc.
• 34. Novartis Group
• 35. Otsuka Pharmaceutical Co., Ltd.
• 36. Pfizer Inc.
• 37. Priavoid GmbH
• 38. Reliance Formulations Pvt. Ltd.
• 39. Sanofi S.A.
• 40. Servier Laboratories (Aust) Pty Ltd
• 41. Shine Pharmaceuticals Ltd.
• 42. Somacare
• 43. SteriMax Inc.
• 44. Sun Pharmaceuticals Pvt Ltd.
• 45. Takeda Pharmaceutical Co. Ltd.
• 46. Teva Pharmaceutical Industries Ltd.
• 47. Torrent Pharmaceuticals Ltd.
• 48. UCB S.A.
• 49. Wellona Pharma
• 50. Zee Laboratories Limited